Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states

Atherosclerosis

Volumn 139, Issue 1, 1998, Pages 77-82

  James, Richard W ^a   Blatter Garin, Marie Claude ^a   Calabresi, Laura ^b   Miccoli, Roberto ^c   Von Eckardstein, Arnold ^d   Tilly Kiesi, Marju ^e   Taskinen, Marja Riitta ^e   Assmann, Gerd ^d   Franceschini, Guido ^b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Apolipoprotein A I; Atherosclerosis; Genetic polymorphisms; Lipoproteins; Oxidative stress; Tangier's disease

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; ARYLESTERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID PEROXIDATION; LIPOPROTEIN DEFICIENCY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; TANGIER DISEASE;

ADULT; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; BLOTTING, WESTERN; ESTERASES; FEMALE; HUMANS; HYPOLIPOPROTEINEMIAS; MALE; MIDDLE AGED; TANGIER DISEASE;

EID: 0032126007     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00058-6     Document Type: Article

References (39)

1. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:1991;2152-2154.
2. Watson A.D., Berliner J.A., Hama S.Y. et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidised low density lipoprotein. J Clin Invest. 96:1995;2882-2891.
3. Ruiz J., Blanché H., James R.W. et al. The polymorphism (Gln-Arg192) of the high-density lipoprotein-bound enzyme paraoxonase is an independent cardiovascular risk factor in non-insulin dependent diabetic patients. Lancet. 346:1995;869-872.
4. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease. J Clin Invest. 96:1995;3005-3008.
5. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetic patients. J Clin Endocrinol Metab. 82:1997;2257-2260.
6. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphisms of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 17:1997;1067-1073.
7. Antikainen M., Murtomaki S., Syvänne M. et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with risk of coronary artery disease in Finns. J Clin Invest. 98:1996;883-885.
8. Herrmann S-M., Blanc H., Poirier O. et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. 126:1996;299-304.
9. Blatter M-C., James R.W., Messmer S., Barja F., Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem. 211:1993;871-879.
10. Kelso G.J., Stuart W.D., Richter R.J., Furlong C.E., Jordan-Starck T.C., Harmony J.A.K. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33:1994;832-839.
11. Banka C.L. High density lipoproteins and lipoprotein oxidation. Curr Opin Lipidol. 7:1996;139-142.
12. Blatter Garin M-C., Abbot C., Messmer S. et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 304:1994;549-554.
13. Mackness M.I., Walker C.H., Carlson L.A. Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem. 33:1987;587-588.
14. Mackness M.I., Peuchant E., Dumon M-F., Walker C.H., Clerc M. Absence of 'A'-esterase activity in the serum of a patient with Tangier disease. Clin Biochem. 22:1989;475-478.
15. Mackness M.I., Thompson H.M., Hardy A.R., Walker C.H. Distinction between 'A'-esterases and arylesterases. Biochem J. 245:1987;293-296.
16. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos. 19:1991;100-106.
17. Schmitz G., Assmann G., Robenek H., Brennhausen B. Tangier disease: a disorder of intracellular membrane traffic. Proc Natl Acad Sci USA. 82:1985;6305-6309.
18. Miccoli R., Bertolotto A., Navalesi R. et al. Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation. 94:1996;1622-1628.
19. Tilly-Kiesi M., Zhang Q., Ehnholm S. et al. Apo A-I Helsinki (Lys107'0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency. Arterioscler Thromb Vasc Biol. 15:1995;1294-1306.
20. Franceschini G., Sirtori C.R., Capurso A., Weisgraber K.H., Mahley R.W. A-I Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 66:1980;892-900.
21. Weisgraber K.H., Bersot T.P., Mahley R.W., Franceschini G., Sirtori C.R. A-I Milano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest. 66:1980;901-907.
22. Blatter Garin M-C., James R.W., Dussoix P. et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 99:1997;62-66.
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
24. James R.W., Proudfoot A., Pometta D. Immunoaffinity fractionation of high density lipoprotein subclasses 2 and 3 using anti-apolipoprotein A-I and A-II immunosorbent gels. Biochim Biophys Acta. 1002:1989;292-301.
25. James R.W., Pometta D. Differences in lipoprotein subfraction composition and distribution between type 1 diabetic men and control subjects. Diabetes. 39:1990;1158-1164.
26. James R.W., Pometta D. The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 34:1991;246-252.
27. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 52:1993;598-608.
28. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 3:1993;73-76.
29. Eckerson H.W., Romson J., Wyte C., La Du B.N. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet. 35:1983;214-227.
30. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 15:1995;1812-1818.
31. James R.W., Blatter Garin M-C., von Eckardstein A., Calabresi L., Assman G., Franceschini G. Modulated activity and concentration of paraoxonase in AIMilano patients compared to other HDL deficiencies. Circulation. 94:1996;1222.
32. Franceschini G., Calabresi L., Tosi C., Gianfranceschi G., Sirtori C.R., Nichols A.V. Apolipoprotein A-I Milano. Disulfide-linked dimers increase high density lipoprotein stability and hinder particle interconversion in carrier plasma. J Biol Chem. 265:1990;12224-12231.
33. Mackness M.I., Hallam S.D., Peard T., Warner S., Walker C.H. The separation of sheep and human serum 'A'-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol. 82:1985;675-677.
34. Mackness M.I., Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243-253.
35. Castro G.R., Fielding C.J. Early incorporation of cell-derived cholesterol into pre-béta-migrating high density lipoprotein. Biochemistry. 27:1988;25-29.
36. von Eckardstein A., Huang Y., Wu S., Funke H., Noseda G., Assmann G. Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency. Arterioscler Thromb Vasc Biol. 15:1995;691-703.
37. von Eckardstein A., Huang Y., Wu S. et al. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arterioscler Thromb Vasc Biol. 15:1995;1755-1763.
38. Sorenson R.C., Primo-Parmo S.L., Kuo C-L., Adkins S., Lockridge O., La Du B.N. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci USA. 92:1995;7187-7191.
39. Vega G.L., Grundy S.M. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol. 7:1996;209-216.